Fluocinonide : interactions médicamenteuses

Fluocinonide (Lidex, Vanos), corticoïde, présente 309 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 29 de niveau majeur, 193 de niveau modéré, 87 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (29)

  • Abiratéroneinhibiteur du CYP2D6Majeure

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (notice Abiratérone, Mises en garde et précautions)

  • AdalimumabimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Adalimumab, Mise en garde encadrée)

  • AdrénalinesympathomimétiqueMajeure

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (notice Adrénaline, Interactions médicamenteuses)

  • Arformotérolagoniste bêta-adrénergiqueMajeure

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (notice Arformotérol, Contre-indications)

  • AtazanavirantirétroviralMajeure

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (notice Atazanavir, Interactions médicamenteuses)

  • AxitinibMajeure

    Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (notice Axitinib, Mises en garde et précautions)

  • Baricitinibinhibiteur de JAKMajeure

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Baricitinib, Mise en garde encadrée)

  • DocétaxelMajeure

    Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)

  • …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (notice Emtricitabine, rilpivirine et ténofovir, Contre-indications)

  • ÉtanerceptimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Étanercept, Mise en garde encadrée)

  • Formotérolagoniste bêta-adrénergiqueMajeure

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (notice Formotérol, Contre-indications)

  • FosamprénavirantirétroviralMajeure

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Fosamprénavir, Interactions médicamenteuses)

  • InfliximabimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Infliximab, Mise en garde encadrée)

  • Kétoconazoleantifongique azoléMajeure

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Kétoconazole, Interactions médicamenteuses)

  • LovastatinestatineMajeure

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (notice Lovastatine, Contre-indications)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (notice Mifépristone, Mise en garde encadrée)

  • Mitotaneinducteur du CYP3A4Majeure

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (notice Mitotane, Mise en garde encadrée)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (notice Moexipril, Mises en garde)

  • RilpivirineantirétroviralMajeure

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (notice Rilpivirine, Contre-indications)

  • Salmétérolagoniste bêta-adrénergiqueMajeure

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (notice Salmétérol, Mise en garde encadrée)

  • SirolimusimmunosuppresseurMajeure

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (notice Sirolimus, Mises en garde et précautions)

  • Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (notice Somatropine, Interactions médicamenteuses)

  • TocilizumabimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tocilizumab, Mise en garde encadrée)

  • TofacitinibimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tofacitinib, Mise en garde encadrée)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (notice Trandolapril, Mises en garde)

  • TrétinoïnerétinoïdeMajeure

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

  • Trioxyde d'arsenicmédicament allongeant l'intervalle QTMajeure

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (notice Trioxyde d'arsenic, Mise en garde encadrée)

  • Uméclidinium et vilantérolanticholinergiqueMajeure

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (notice Uméclidinium et vilantérol, Contre-indications)

  • UpadacitinibimmunosuppresseurMajeure

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Upadacitinib, Mise en garde encadrée)

Interactions modérées (193)

  • Acide alendroniquebisphosphonateModérée

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide alendronique, Mises en garde et précautions)

  • Acide ibandroniquebisphosphonateModérée

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide ibandronique, Mises en garde et précautions)

  • Acide méfénamiqueAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (notice Acide méfénamique, Mises en garde et précautions)

  • Acide pamidroniquebisphosphonateModérée

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (notice Acide pamidronique, Mises en garde et précautions)

  • Acide risédroniquebisphosphonateModérée

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (notice Acide risédronique, Mises en garde et précautions)

  • Acide valproïqueanticonvulsivantModérée

    Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (notice Acide valproïque, Interactions médicamenteuses)

  • Acide zolédroniquebisphosphonateModérée

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (notice Acide zolédronique, Mises en garde et précautions)

  • AclidiniumanticholinergiqueModérée

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

  • AfatinibModérée

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (notice Afatinib, Mises en garde et précautions)

  • AlbendazoleModérée

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (notice Albendazole, Mises en garde et précautions)

  • AlemtuzumabimmunosuppresseurModérée

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (notice Alemtuzumab, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (notice Aliskirène, Mises en garde et précautions)

  • Alogliptine et metformineinhibiteur de la DPP-4Modérée

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (notice Alogliptine et metformine, Interactions médicamenteuses)

  • AlpélisibModérée

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

  • Amphotéricine BantifongiqueModérée

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (notice Amphotéricine B, Interactions médicamenteuses)

  • AspirineAINSModérée

    The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (notice Aspirine, Mises en garde)

  • Azélastine et fluticasoneantihistaminiqueModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • BéclométasonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Belladone et opiumopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Belladone et opium, Mises en garde et précautions)

  • BendamustineModérée

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (notice Bendamustine, Mises en garde et précautions)

  • BenralizumabModérée

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (notice Benralizumab, Mises en garde et précautions)

  • BétaméthasonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

  • BudésonidecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Budésonide et formotérolcorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • BuprénorphineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine, Mises en garde et précautions)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine et naloxone, Mises en garde et précautions)

  • BupropionantidépresseurModérée

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (notice Bupropion, Mises en garde et précautions)

  • In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. (notice Butalbital, aspirine et caféine, Interactions médicamenteuses)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butalbital, aspirine, caféine et codéine, Mises en garde et précautions)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butalbital, paracétamol, caféine et codéine, Mises en garde et précautions)

  • ButorphanolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butorphanol, Mises en garde)

  • CéfoxitinecéphalosporineModérée

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (notice Céfoxitine, Mises en garde et précautions)

  • CélécoxibAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Célécoxib, Mises en garde et précautions)

  • CiclésonidecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • CiclosporineimmunosuppresseurModérée

    …in perfusion > decrease in tubular function Increased uptake of Indium 111 labeled platelets or Tc-99m in colloid Therapy Responds to decreased cyclosporine Responds to increased steroids or antilymphocyte globulin A form of a cyclosporine-associated nephropathy is characterized by serial deterioration in renal function and morphologic changes in the kidneys. (notice Ciclosporine, Mises en garde)

  • CiprofloxacinefluoroquinoloneModérée

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ciprofloxacine, Mises en garde et précautions)

  • CladribineantimétaboliteModérée

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (notice Cladribine, Interactions médicamenteuses)

  • ClobétasolcorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Cocaïneanesthésique localModérée

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (notice Cocaïne, Interactions médicamenteuses)

  • CodéineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Codéine, Mises en garde et précautions)

  • CytarabineantimétaboliteModérée

    These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (notice Cytarabine, Mises en garde)

  • DaptomycineantibiotiqueModérée

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (notice Daptomycine, Mises en garde et précautions)

  • DarunavirantirétroviralModérée

    Corticosteroids: dexamethasone (systemic) ↓ darunavir Co-administration of PREZISTA/ritonavir with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to darunavir. (notice Darunavir, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralModérée

    Corticosteroids: dexamethasone (systemic) Corticosteroids primarily metabolized by CYP3A: e.g. betamethasone budesonide ciclesonide fluticasone methylprednisolone mometasone triamcinolone ↓ darunavir ↓ cobicistat ↑ corticosteroids Co-administration with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic… (notice Darunavir et cobicistat, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferModérée

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (notice Déférasirox, Mises en garde et précautions)

  • DéflazacortcorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • DénosumabModérée

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (notice Dénosumab, Mises en garde et précautions)

  • Désogestrel et éthinylestradiolcontraceptif oralModérée

    Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (notice Désogestrel et éthinylestradiol, Précautions)

  • DésonidecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • DexaméthasonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • The amount of both steroids should be considered in the choice of an oral contraceptive. (notice Diacétate d'étynodiol et éthinylestradiol, Mises en garde)

  • DiclofénacAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac, Mises en garde et précautions)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac et misoprostol, Mises en garde et précautions)

  • DicyclovérineanticholinergiqueModérée

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (notice Dicyclovérine, Interactions médicamenteuses)

  • DiflunisalAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Diflunisal, Mises en garde)

  • Digoxineglycoside digitaliqueModérée

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (notice Digoxine, Mises en garde et précautions)

  • DupilumabModérée

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (notice Dupilumab, Mises en garde et précautions)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

  • Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↓ elvitegravir ↓ cobicistat ↑ corticosteroids Coadministration with oral dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to elvitegravir. (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

  • ErlotinibModérée

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (notice Erlotinib, Mises en garde et précautions)

  • EstradiolestrogèneModérée

    Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estradiol, Précautions)

  • Estradiol et diénogestcontraceptif oralModérée

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (notice Estradiol et diénogest, Interactions médicamenteuses)

  • Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estradiol et noréthistérone, Mises en garde et précautions)

  • Estrogènes conjuguésestrogèneModérée

    Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (notice Estrogènes conjugués, Précautions)

  • Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (notice Estrogènes conjugués et bazédoxifène, Mises en garde et précautions)

  • ÉtodolacAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Étodolac, Mises en garde)

  • ÉtravirineantirétroviralModérée

    Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (notice Étravirine, Interactions médicamenteuses)

  • FénoprofèneAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Fénoprofène, Mises en garde et précautions)

  • FentanylopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Fentanyl, Mises en garde et précautions)

  • FingolimodimmunosuppresseurModérée

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (notice Fingolimod, Mises en garde et précautions)

  • FludrocortisonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • FlunisolidecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • FlurbiprofèneAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (notice Flurbiprofène, Mises en garde et précautions)

  • FluticasonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Fluticasone et salmétérolcorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • FosphénytoïneanticonvulsivantModérée

    Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (notice Fosphénytoïne, Interactions médicamenteuses)

  • Glimépiridesulfamide hypoglycémiantModérée

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (notice Glimépiride, Interactions médicamenteuses)

  • Glipizidesulfamide hypoglycémiantModérée

    …examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin,… (notice Glipizide, Interactions médicamenteuses)

  • HalobétasolcorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • HalopéridolantipsychotiqueModérée

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (notice Halopéridol, Interactions médicamenteuses)

  • HydralazinevasodilatateurModérée

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (notice Hydralazine, Mises en garde)

  • HydrocodoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone, Mises en garde et précautions)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et chlorphénamine, Mises en garde et précautions)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et homatropine, Mises en garde et précautions)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et ibuprofène, Mises en garde)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et paracétamol, Mises en garde)

  • HydrocortisonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • HydromorphoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydromorphone, Mises en garde et précautions)

  • IbuprofèneAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène, Mises en garde et précautions)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène et famotidine, Mises en garde et précautions)

  • Imatinibinhibiteur du CYP3A4Modérée

    If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (notice Imatinib, Mises en garde et précautions)

  • IndométacineAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Indométacine, Mises en garde et précautions)

  • Insuline asparteinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (notice Insuline asparte, Interactions médicamenteuses)

  • Insuline dégludecinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (notice Insuline dégludec, Interactions médicamenteuses)

  • Insuline détémirinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (notice Insuline détémir, Interactions médicamenteuses)

  • Insuline glargineinsulineModérée

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (notice Insuline glargine, Interactions médicamenteuses)

  • Insuline lisproinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (notice Insuline lispro, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Modérée

    Although other risk factors were present in some cases (such as corticosteroid use and/or exposure to radiation), a possible risk attributable to KALYDECO cannot be excluded. (notice Ivacaftor, Mises en garde et précautions)

  • IvermectineModérée

    Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (notice Ivermectine, Mises en garde)

  • KétoprofèneAINSModérée

    PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (notice Kétoprofène, Mises en garde et précautions)

  • KétorolacAINSModérée

    In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Kétorolac, Mises en garde et précautions)

  • LénacapavirantirétroviralModérée

    Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Lénacapavir, Interactions médicamenteuses)

  • LévofloxacinefluoroquinoloneModérée

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Lévofloxacine, Mises en garde et précautions)

  • Lévonorgestrel et éthinylestradiolcontraceptif oralModérée

    Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (notice Lévonorgestrel et éthinylestradiol, Interactions médicamenteuses)

  • LévorphanolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Lévorphanol, Mises en garde)

  • Lévosalbutamolagoniste bêta-adrénergiqueModérée

    If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Lévosalbutamol, Mises en garde et précautions)

  • Lévothyroxinehormone thyroïdienneModérée

    Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (notice Lévothyroxine, Mises en garde et précautions)

  • Lévothyroxine et liothyroninehormone thyroïdienneModérée

    The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

  • Liothyroninehormone thyroïdienneModérée

    Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. (notice Liothyronine, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (notice Lisinopril et hydrochlorothiazide, Mises en garde)

  • Lopinavir et ritonavirantirétroviralModérée

    …Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↓ lopinavir ↑ glucocorticoids Coadministration with oral dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to lopinavir. (notice Lopinavir et ritonavir, Interactions médicamenteuses)

  • MargétuximabModérée

    In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (notice Margétuximab, Mises en garde et précautions)

  • MédroxyprogestéroneprogestatifModérée

    MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (notice Médroxyprogestérone, Mises en garde et précautions)

  • MégestrolprogestatifModérée

    Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (notice Mégestrol, Mises en garde et précautions)

  • MéloxicamAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Méloxicam, Mises en garde et précautions)

  • MépolizumabModérée

    Decrease corticosteroids gradually, if appropriate. (notice Mépolizumab, Mises en garde et précautions)

  • MéthadoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Méthadone, Mises en garde et précautions)

  • Méthazolamideinhibiteur de l'anhydrase carboniqueModérée

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (notice Méthazolamide, Interactions médicamenteuses)

  • MéthotrexateimmunosuppresseurModérée

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (notice Méthotrexate, Interactions médicamenteuses)

  • MéthyldopaantihypertenseurModérée

    If not, corticosteroids may be given and other causes of anemia should be considered. (notice Méthyldopa, Mises en garde)

  • MéthylprednisolonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • MéthyltestostéroneandrogèneModérée

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

  • Métolazonediurétique thiazidiqueModérée

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (notice Métolazone, Interactions médicamenteuses)

  • MétyraponeModérée

    This can be corrected by giving appropriate doses of corticosteroids. (notice Métyrapone, Mises en garde et précautions)

  • MométasonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Montélukastantagoniste des récepteurs des leucotriènesModérée

    Inhaled corticosteroid may be reduced gradually. (notice Montélukast, Mises en garde et précautions)

  • MorphineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Morphine, Mises en garde et précautions)

  • MoxifloxacinefluoroquinoloneModérée

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Moxifloxacine, Mises en garde et précautions)

  • NabumétoneAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Nabumétone, Mises en garde)

  • NalbuphineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Nalbuphine, Mises en garde)

  • Naltrexone et bupropionantagoniste des opioïdesModérée

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (notice Naltrexone et bupropion, Mises en garde et précautions)

  • NaproxèneAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène, Mises en garde et précautions)

  • Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène et ésoméprazole, Mises en garde et précautions)

  • NatalizumabimmunosuppresseurModérée

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (notice Natalizumab, Mises en garde et précautions)

  • NatéglinideglinideModérée

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (notice Natéglinide, Interactions médicamenteuses)

  • NintédanibModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Nirmatrelvir et ritonavirantiviralModérée

    Corticosteroids primarily metabolized by CYP3A betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, triamcinolone ↑ corticosteroid Co-administration with corticosteroids (all routes of administration) of which exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome… (notice Nirmatrelvir et ritonavir, Interactions médicamenteuses)

  • OcrélizumabimmunosuppresseurModérée

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (notice Ocrélizumab, Mises en garde et précautions)

  • OfloxacinefluoroquinoloneModérée

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ofloxacine, Mises en garde)

  • OlicéridineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Olicéridine, Mises en garde et précautions)

  • Olopatadine et mométasoneantihistaminiqueModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • OmalizumabModérée

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (notice Omalizumab, Mises en garde et précautions)

  • OxaprozineAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Oxaprozine, Mises en garde et précautions)

  • OxycodoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone, Mises en garde et précautions)

  • Oxycodone et paracétamolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone et paracétamol, Mises en garde et précautions)

  • OxymorphoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxymorphone, Mises en garde et précautions)

  • Paracétamol et codéineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Paracétamol et codéine, Mises en garde)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Paracétamol et ibuprofène, Mises en garde et précautions)

  • PasiréotideModérée

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (notice Pasiréotide, Mises en garde et précautions)

  • Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (notice Pénicillamine, Mises en garde)

  • Pentazocine et naloxoneopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Pentazocine et naloxone, Mises en garde)

  • PéthidineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Péthidine, Mises en garde et précautions)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de glycérol, Interactions médicamenteuses)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de sodium, Interactions médicamenteuses)

  • PhényléphrinedécongestionnantModérée

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (notice Phényléphrine, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantModérée

    Warfarin Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban… (notice Phénytoïne, Interactions médicamenteuses)

  • Pioglitazone et glimépiridethiazolidinedioneModérée

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

  • PiroxicamAINSModérée

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Piroxicam, Mises en garde et précautions)

  • PonésimodimmunosuppresseurModérée

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (notice Ponésimod, Mises en garde et précautions)

  • PrednisolonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • PrednisonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Prométhazine et codéineopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Prométhazine et codéine, Mises en garde et précautions)

  • Propofoldépresseur du SNCModérée

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (notice Propofol, Mises en garde et précautions)

  • RifampicineantibiotiqueModérée

    …Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (notice Rifampicine, Interactions médicamenteuses)

  • RifapentineantibiotiqueModérée

    …Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (notice Rifapentine, Interactions médicamenteuses)

  • RitonavirantirétroviralModérée

    Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↑ glucocorticoids Coadministration with corticosteroids whose exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome and adrenal suppression.Alternative… (notice Ritonavir, Interactions médicamenteuses)

  • Rocuroniumbloquant neuromusculaireModérée

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (notice Rocuronium, Mises en garde et précautions)

  • Salbutamolagoniste bêta-adrénergiqueModérée

    If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Salbutamol, Mises en garde et précautions)

  • SalsalateAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Salsalate, Mises en garde)

  • SulindacAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Sulindac, Mises en garde)

  • Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Sumatriptan et naproxène, Mises en garde et précautions)

  • Suxaméthoniumbloquant neuromusculaireModérée

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (notice Suxaméthonium, Interactions médicamenteuses)

  • TapentadolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tapentadol, Mises en garde et précautions)

  • TémozolomideModérée

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (notice Témozolomide, Mises en garde et précautions)

  • TemsirolimusModérée

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (notice Temsirolimus, Mises en garde et précautions)

  • Terbutalineagoniste bêta-adrénergiqueModérée

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Terbutaline, Mises en garde)

  • Tériparatidehormone thyroïdienneModérée

    Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

  • Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

  • TestostéroneandrogèneModérée

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (notice Testostérone, Mises en garde et précautions)

  • ThéophyllineméthylxanthineModérée

    Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (notice Théophylline, Mises en garde)

  • TiotropiumanticholinergiqueModérée

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

  • TolmétineAINSModérée

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Tolmétine, Mises en garde)

  • Torasémidediurétique de l'anseModérée

    Corticosteroids and ACTH: Increased risk of hypokalemia. (notice Torasémide, Interactions médicamenteuses)

  • TramadolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol, Mises en garde et précautions)

  • Tramadol et paracétamolopioïdeModérée

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol et paracétamol, Mises en garde et précautions)

  • TrastuzumabModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • TriamcinolonecorticoïdeModérée

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (notice Triamtérène et hydrochlorothiazide, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléModérée

    • Adrenal Dysfunction : Carefully monitor patients receiving voriconazole and corticosteroids (via all routes of administration) for adrenal dysfunction both during and after voriconazole treatment. (notice Voriconazole, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (notice Warfarine, Interactions médicamenteuses)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (notice Zénocutuzumab, Mises en garde et précautions)

Mentions mineures (87)

  • AcarboseantidiabétiqueMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (notice Acarbose, Interactions médicamenteuses)

  • Acide bempédoïqueinhibiteur de l'OATP1B1Mineure

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (notice Acide bempédoïque, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • AltéplaseMineure

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (notice Altéplase, Mises en garde et précautions)

  • AmikacineaminosideMineure

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (notice Amikacine, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueMineure

    Antithyroid drugs, β-adrenergic blockers, temporary corticosteroid therapy may be necessary to treat the symptoms of hyperthyroidism. (notice Amiodarone, Mises en garde et précautions)

  • Amphétaminestimulant du SNCMineure

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine, Interactions médicamenteuses)

  • Amphétamine et dexamfétaminestimulant du SNCMineure

    Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine et dexamfétamine, Interactions médicamenteuses)

  • Ampicillineantibiotique de la famille des pénicillinesMineure

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Ampicilline, Mises en garde)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (notice Bévacizumab, Mises en garde et précautions)

  • Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (notice Bisoprolol et hydrochlorothiazide, Précautions)

  • BusulfanMineure

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (notice Busulfan, Mises en garde)

  • Calcitriolanalogue de la vitamine DMineure

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (notice Calcitriol, Interactions médicamenteuses)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Steroids or Adrenocorticotropic Hormone – Hypokalemia may develop during concomitant use of steroids or adrenocorticotropic hormone (ACTH). (notice Candésartan et hydrochlorothiazide, Interactions médicamenteuses)

  • Cannabidiol (sur ordonnance)anticonvulsivantMineure

    Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (notice Cannabidiol (sur ordonnance), Mises en garde et précautions)

  • CarbamazépineanticonvulsivantMineure

    …clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (notice Carbamazépine, Interactions médicamenteuses)

  • CéfaclorcéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfaclor, Mises en garde)

  • CéfadroxilcéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfadroxil, Mises en garde et précautions)

  • CefdinircéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefdinir, Mises en garde)

  • CéfotétancéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfotétan, Mises en garde)

  • CefprozilcéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefprozil, Mises en garde)

  • CeftazidimecéphalosporineMineure

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Ceftazidime, Mises en garde)

  • CeftriaxonecéphalosporineMineure

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (notice Ceftriaxone, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueMineure

    Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. (notice Chlorothiazide, Interactions médicamenteuses)

  • ClofarabineantimétaboliteMineure

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (notice Clofarabine, Mises en garde et précautions)

  • Clomifènemodulateur sélectif des récepteurs aux estrogènesMineure

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (notice Clomifène, Mises en garde)

  • Clotrimazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (notice Corticotropine, Mises en garde et précautions)

  • Dapagliflozine et metformineinhibiteur du SGLT2Mineure

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Dapagliflozine et metformine, Interactions médicamenteuses)

  • DasatinibMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • Dexamfétaminestimulant du SNCMineure

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Dexamfétamine, Interactions médicamenteuses)

  • Dropéridolantagoniste de la dopamineMineure

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (notice Dropéridol, Interactions médicamenteuses)

  • Drospirénone et éthinylestradiolcontraceptif oralMineure

    Steroid hormones may be poorly metabolized in patients with impaired liver function. (notice Drospirénone et éthinylestradiol, Mises en garde et précautions)

  • Éconazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • ÉfavirenzantirétroviralMineure

    Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (notice Éfavirenz, Mises en garde et précautions)

  • Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (notice Éfavirenz, lamivudine et ténofovir, Mises en garde et précautions)

  • Empagliflozine et metformineinhibiteur du SGLT2Mineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Empagliflozine et metformine, Interactions médicamenteuses)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. (notice Énalapril et hydrochlorothiazide, Interactions médicamenteuses)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Étonogestrel et éthinylestradiol, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMineure

    Corticosteroids may be indicated until clinical symptoms resolve. (notice Évérolimus, Mises en garde et précautions)

  • Fluconazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • FludarabineantimétaboliteMineure

    Steroids may or may not be effective in controlling these hemolytic episodes. (notice Fludarabine, Mises en garde et précautions)

  • FluoxétineISRSMineure

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Fluoxétine, Mises en garde et précautions)

  • Glibenclamidesulfamide hypoglycémiantMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glibenclamide, Interactions médicamenteuses)

  • Glibenclamide et metforminesulfamide hypoglycémiantMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Glibenclamide et metformine, Interactions médicamenteuses)

  • Glipizide et metforminesulfamide hypoglycémiantMineure

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glipizide et metformine, Précautions)

  • GlucagonMineure

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (notice Glucagon, Mises en garde et précautions)

  • GuselkumabimmunosuppresseurMineure

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (notice Guselkumab, Mises en garde et précautions)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (notice Insuline rapide (humaine), Interactions médicamenteuses)

  • IpratropiumanticholinergiqueMineure

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (notice Lénalidomide, Mises en garde et précautions)

  • Linagliptine et metformineinhibiteur de la DPP-4Mineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Linagliptine et metformine, Interactions médicamenteuses)

  • MelphalanMineure

    The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (notice Melphalan, Mises en garde)

  • MetforminebiguanideMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Metformine, Interactions médicamenteuses)

  • Méthamphétaminestimulant du SNCMineure

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Méthamphétamine, Interactions médicamenteuses)

  • MéthohexitalbarbituriqueMineure

    Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (notice Méthohexital, Mises en garde)

  • Miconazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • Midodrineagoniste alpha-adrénergiqueMineure

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (notice Midodrine, Interactions médicamenteuses)

  • Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (notice Mitoxantrone, Interactions médicamenteuses)

  • Naltrexoneantagoniste des opioïdesMineure

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (notice Naltrexone, Mises en garde et précautions)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norelgestromine et éthinylestradiol, Interactions médicamenteuses)

  • Steroid hormones may be poorly metabolized in patients with impaired liver function. (notice Noréthistérone et éthinylestradiol, Mises en garde et précautions)

  • Norgestimate et éthinylestradiolcontraceptif oralMineure

    Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norgestimate et éthinylestradiol, Interactions médicamenteuses)

  • Norgestrel et éthinylestradiolcontraceptif oralMineure

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (notice Norgestrel et éthinylestradiol, Précautions)

  • Olanzapine et fluoxétineantipsychotiqueMineure

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Olanzapine et fluoxétine, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (notice Olmésartan et hydrochlorothiazide, Interactions médicamenteuses)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (notice Olmésartan, amlodipine et hydrochlorothiazide, Interactions médicamenteuses)

  • Oxacillineantibiotique de la famille des pénicillinesMineure

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (notice Oxacilline, Mises en garde)

  • Pénicilline Gantibiotique de la famille des pénicillinesMineure

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (notice Pénicilline G, Mises en garde)

  • Pénicilline Vantibiotique de la famille des pénicillinesMineure

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Pénicilline V, Mises en garde)

  • Pioglitazone et metforminethiazolidinedioneMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Pioglitazone et metformine, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléMineure

    Concomitant Skin Infections If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. (notice Fluocinonide, Mises en garde et précautions)

  • PropylthiouracileantithyroïdienMineure

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Propylthiouracile, Mises en garde)

  • QuinineantipaludiqueMineure

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (notice Quinine, Interactions médicamenteuses)

  • Raloxifènemodulateur sélectif des récepteurs aux estrogènesMineure

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (notice Raloxifène, Interactions médicamenteuses)

  • RépaglinideglinideMineure

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (notice Répaglinide, Interactions médicamenteuses)

  • RituximabimmunosuppresseurMineure

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (notice Rituximab, Mises en garde et précautions)

  • Saxagliptine et metformineinhibiteur de la DPP-4Mineure

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Saxagliptine et metformine, Interactions médicamenteuses)

  • Sitagliptine et metformineinhibiteur de la DPP-4Mineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Sitagliptine et metformine, Interactions médicamenteuses)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMineure

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur. (notice Spironolactone et hydrochlorothiazide, Interactions médicamenteuses)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (notice Ténectéplase, Mises en garde et précautions)

  • ThiamazoleantithyroïdienMineure

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Thiamazole, Mises en garde)

  • TobramycineaminosideMineure

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

  • UstékinumabimmunosuppresseurMineure

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (notice Ustékinumab, Mises en garde et précautions)

  • Vitamine DVitamines et minérauxMineure

    Les corticoïdes tels que la prednisone réduisent l'absorption du calcium et perturbent le métabolisme de la vitamine D, ce qui contribue à la perte osseuse. (NIH Office of Dietary Supplements, Vitamin D)

  • ZiprasidoneantipsychotiqueMineure

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (notice Ziprasidone, Mises en garde et précautions)

Vérifiez Fluocinonide avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.